Abcam, ab284863, Anti-Thymidine Phosphorylase antibody [EPR25629-129] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Thymidine Phosphorylase antibody. Carrier free. Suitable for ICC/IF, IP, WB, IHC-P, Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25629-129,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IP, ICC/IF, Flow Cyt (Intra), IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab284863 is the carrier-free version of
ab284861
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Thymidine phosphorylase also known as platelet-derived endothelial cell growth factor (PD-ECGF) acts mechanically to catalyze the reversible phosphorolysis of thymidine into thymine and 2-deoxy-alpha-D-ribose-1-phosphate. With a mass of approximately 44 kDa this enzyme is present in various tissues including blood vessels and macrophages. Its expression tends to be higher in tumor tissues which suggests a specific role in cancer biology.
Biological function summary
The enzyme participates in pyrimidine nucleoside metabolism providing an alternate route for thymidine catabolism. It is not part of a larger complex functioning independently to promote angiogenesis. Thymidine phosphorylase enhances the degradation of extracellular thymidine which can positively impact nucleotide balance within cells aiding DNA synthesis and repair.
Pathways
Thymidine phosphorylase operates significantly within the nucleotide salvage pathways. It is essential for clarifying thymidine availability for DNA synthesis. The enzyme links with enzymes like dihydropyrimidine dehydrogenase in pyrimidine degradation playing a critical role in maintaining cellular nucleotide homeostasis.
Altered activity of thymidine phosphorylase correlates with cancer and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). In tumors increased levels of this enzyme facilitate angiogenesis contributing to tumor growth and metastasis. In MNGIE mutations in this enzyme lead to imbalances in nucleotides causing mitochondrial dysfunction. The enzyme's dysregulation connects to angiogenesis-related proteins like VEGF in cancer highlighting potential therapeutic targets.